4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.
4D Molecular Therapeutics has raised $200.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in June 2026.
4D Molecular Therapeutics's investors include Janus Henderson Investors, Perceptive Advisors, Mirae Asset, Hercules Capital, Casdin Capital.
4D Molecular Therapeutics is headquartered in Emeryville, United States.
4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.
4D Molecular Therapeutics is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"4D Molecular Therapeutics — Funding & Investors." VCBacked, June 29, 2026, https://www.vcbacked.co/company/4d-molecular-therapeutics. Accessed August 14, 2026.
VCBacked. (2026). 4D Molecular Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/4d-molecular-therapeutics
{{cite web |title=4D Molecular Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/4d-molecular-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated